Compare Sanofi SA (SNY) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Wheaton Precious Metals Corp — how do they compare? Sanofi SA trades at $43.59 (market cap $104.30B), while Wheaton Precious Metals Corp trades at $134.54 (market cap $60.94B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | WPM | |
|---|---|---|
Market Cap | $104.30B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $52.34 | $165.72 |
52-Week Low | $41.33 | $91.02 |
Enterprise Value | $124.19B | $62.82B |
Dividend Yield | 5.55% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Wheaton Precious Metals (WPM) trades at $135.51, up 1.59% on the day, reflecting strong momentum amid record financial performance. The stock exhibits a bullish technical trend, supported by consecutive earnings beats and robust cash flow growth. Recent results highlight significant revenue and profit expansion, driven by higher metal prices and increased sales volumes. Analyst sentiment remains overwhelmingly positive, with a consensus Buy rating and a price target implying substantial upside potential.
The outlook for WPM is favorable, underpinned by its high-margin streaming model and exposure to rising precious metal prices. Key opportunities include sustained earnings growth and strategic deal capacity, while risks involve commodity price volatility and execution of future streaming agreements. The stock's current valuation multiples suggest premium pricing, requiring continued operational excellence to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
